Abstract
Mammalian target of rapamycin (mTOR) locates at the downstream of phosphatidylinositol 3 kinase (PI3K)-protein kinase B (Akt) cell signal transduction pathway. Studies find that the abnormal activation of this pathway is correlated with the endocrine and drug resistance of anti human epidermal growth factor receptor-2 (HER-2) target therapy in breast cancer. The combination with mTOR inhibitors based on the past traditional drugs can block the pathway and reflect a favourable application prospect in preventing the development of resistance and restoring the initial sensitivity on tumor cells. mTOR inhibitors are expected to be the new hope for the treatment of breast cancer. Key words: Breast neoplasms; Sirolimus; mTOR inhibitor
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
